6.55
-0.15(-2.24%)
Currency In USD
| Previous Close | 6.7 |
| Open | 6.7 |
| Day High | 6.74 |
| Day Low | 6.53 |
| 52-Week High | 15.47 |
| 52-Week Low | 3.76 |
| Volume | 2.62M |
| Average Volume | 1.14M |
| Market Cap | 610.49M |
| PE | -1.51 |
| EPS | -4.35 |
| Moving Average 50 Days | 7.3 |
| Moving Average 200 Days | 6.66 |
| Change | -0.15 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $151.27 as of December 21, 2025 at a share price of $6.55. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $346.93 as of December 21, 2025 at a share price of $6.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 09, 2025 2:00 PM GMT
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer TestSALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
GlobeNewswire Inc.
Nov 25, 2025 9:15 PM GMT
Actionable offering helps enable earlier, more personalized breast cancer interventionsBOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
GlobeNewswire Inc.
Nov 10, 2025 1:30 PM GMT
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk TestSALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medici